Overview

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

Status:
RECRUITING
Trial end date:
2030-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the feasibility of administering DFMO to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
Phase:
PHASE1
Details
Lead Sponsor:
Montefiore Medical Center
Collaborator:
Johns Hopkins University
Treatments:
Eflornithine